Strainprint Technologies partners with Israeli research leaders to study cannabis as a treatment for endometriosis

Twitter icon

Cannabis’ ability to treat numerous illnesses and conditions is becoming more apparent by the day in the wake of legalization and this is especially true for a number of conditions specifically affecting women's health.

More and more women are opting to use cannabis to treat symptoms associated with premenstrual syndrome and menopause, but it’s also having very positive outcomes in treating other conditions that affect women in particular.  As such, Strainprint Technologies Ltd. announced last month that it has partnered with Israel-based research groups, Lumir Lab and Gynica to conduct clinical studies on how cannabis can be used to treat endometriosis. The study will be the first of its kind and will be carried out simultaneously in both Canada and Israel.

Affecting roughly 180 women worldwide, endometriosis is a condition where the tissue of the uterine lining migrates to other organs in the body. It’s estimated that 1 in 10 women between the ages of 15 to 49 will be affected in their lifetime, according to Strainprint Technologies Ltd., a demand-side cannabis data and analytics company.

Story Continues Below

Vice-president of research for Strainprint Michelle Arbus will work with Gynica’s Professor Moshe Hod, president of the European Association of Perinatal Medicine to conduct the study.

“The combination of Strainprint’s big data analytics combined with Gynica’s scientific team and clinical research capabilities create a unique and innovative approach for providing evidence-based products to patients worldwide, and moreover for women who are under-treated by current solutions,” said Hod.

According to Strainprint, four percent of women currently using the Strainprint app are using cannabis to treat endometriosis. Of that number, 14 percent treating the condition are between the ages of 18 and 24, 39 percent are between the ages of 25 and 34, 34 percent are between the ages of 35 and 44, and 12 percent are 45 and older.

"Endometriosis remains one of the most misdiagnosed and least understood medical conditions, and currently, there is no cure," said Professor Hod. "Strainprint's early observational studies show that medical cannabis treatment has a positive effect on symptoms related to endometriosis, but much more research is required. Our objective is to identify which active cannabinoids, terpenes, and flavonoids, in relative combination, provide the most effective relief, reduce pain and prevent reoccurrence."

Gynica Senior scientist, Dr. Sari Prutchi Sagv will develop the joint study protocol that will be used for clinical trial applications in both Canada and Israel. They will first draw data from Strainprint’s more than 900,000 real time patient outcomesin addition to 40 million medical cannabis data points. Lumir Lab will then take this data and validate a formulation to focus on at the study at which point, the groups will use Strainprint’s recently launched community portal to recruit up to 1,000 patients to participate in the trial in each country.


Professor Hanus and Dr. Prutchi Sagiv of Lumir Lab. 

"It's truly amazing for all of us at Strainprint to get to work with this team of world-renowned scientists and doctors on such a significant medical issue," said Strainprint CEO, Andrew Muroff. "We're committed to helping improve the lives of millions of women suffering from endometriosis."

Strainprint, Gynica and Lumir Lab have stated that they expect the study to run in the second quarter of 2019.

e-mail icon Facebook icon Twitter icon LinkedIn icon Reddit icon
Rate this article: 
Regional Marijuana News: